Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas

BACKGROUND. Mibefradil (MIB), previously approved for treatment of hypertension, is a selective T-type calcium channel blocker with preclinical activity in high-grade gliomas (HGGs). To exploit its presumed mechanism of impacting cell cycle activity (G1 arrest), we designed a phase I study to determ...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Neuro Oncol
मुख्य लेखकों: Holdhoff, Matthias, Ye, Xiaobu, Supko, Jeffrey G., Nabors, Louis B., Desai, Arati S., Walbert, Tobias, Lesser, Glenn J., Read, William L., Lieberman, Frank S., Lodge, Martin A., Leal, Jeffrey, Fisher, Joy D., Desideri, Serena, Grossman, Stuart A., Wahl, Richard L., Schiff, David
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Oxford University Press 2017
विषय:
Clinical Investigations
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464434/
https://ncbi.nlm.nih.gov/pubmed/28371832
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox020
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन